# Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap

Page: https://stenobird.com/podcast/the-high-court-report-7304353/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap
Text version: https://stenobird.com/podcast/the-high-court-report-7304353/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap.md
Podcast: [The High Court Report](https://stenobird.com/podcast/the-high-court-report-7304353)
Published: 2026-06-10T09:00:00+00:00
Episode link: https://thehighcourtreport.com//opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap
Audio file: https://episodes.captivate.fm/episode/a7da18ae-95cc-48e7-a1f2-cfb36ad5920f.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-high-court-report-7304353/episodes/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap
Duration seconds: 3738

## Resource

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here | Argued: 04/29/2026 | Decided: 06/04/2026 Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication. Question Presented: Whether a generic drug maker's marketing statements plausibly constitute "active steps" inducing patent infringement under 35 U.S.C. §271(b). Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded. Main Arguments: Petitioner (Hikma): (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b); (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability; (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk. Respondent (Amarin): (1) Hikma's totality of statements — repeatedly invoking "generic Vascepa," using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use; (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders; (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice. Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted ac…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-high-court-report-7304353/episodes/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-high-court-report-7304353/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.